

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

**Financial Statements, Audit Reports and
Supplementary Information in Accordance
With the Uniform Guidance
For the Year Ended September 30, 2023
(With Summarized Information for 2022)
With Independent Auditor's Reports**



MITCHELL TITUS
ACHIEVING EXCELLENCE TOGETHER

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Financial Statements and Additional Information
Year Ended September 30, 2023

TABLE OF CONTENTS

	<u>Page(s)</u>
INDEPENDENT AUDITOR’S REPORT	1–4
FINANCIAL STATEMENTS	
Statements of Financial Position	5–6
Statement of Operations and Changes in Net Assets	7
Statement of Functional Expenses	8
Statements of Cash Flows	9
Notes to Financial Statements	10–27
SUPPLEMENTARY INFORMATION AND INDEPENDENT AUDITOR’S REPORTS	
Schedule of Expenditures of Federal Awards	28–34
Notes to Schedule of Expenditures of Federal Awards	35–38
Independent Auditor’s Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of the Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	39–40
Independent Auditor’s Report on Compliance for Each Major Federal Program and Report on Internal Control over Compliance in Accordance with the Uniform Guidance	41–43
Schedule of Findings and Questioned Costs	44–45
Summary Schedule of Prior-Year Audit Findings	46



INDEPENDENT AUDITOR'S REPORT

To Management and the Board of Directors
Fund for Public Health in New York, Inc.

Report on the Financial Statements

Opinion

We have audited the accompanying financial statements of Fund for Public Health in New York, Inc. (the Organization), which comprise the statements of financial position as of September 30, 2023, the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Fund for Public Health in New York, Inc. as of September 30, 2023, and the changes in its net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization, and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Emphasis of Matter

As discussed in Note 3 to the financial statements, in 2023, the Organization adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)*, as amended. In addition, during 2023, the Organization also adopted FASB ASU No. 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. Our opinion is not modified with respect to these matters.

80 Pine Street
New York, NY 10005
T +1 212 709 4500
F +1 212 709 4680
mitchelltitus.com



Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for one year after the date that the financial statements are issued or are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.



MITCHELL TITUS

- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards (the Schedule) is presented for purposes of additional analysis as required by the audit requirements of Title 2 U.S. *Code of Federal Regulations* (CFR) Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance), and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the Schedule is fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we also have issued our report dated June 28, 2024 on our consideration of the Organization's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Organization's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization's internal control over financial reporting and compliance.



MITCHELL TITUS

Report on Summarized Comparative Information

We have previously audited the Organization's September 30, 2022 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated June 29, 2023. In our opinion, the summarized comparative information presented herein as of and for the year ended September 30, 2022 is consistent, in all material respects, with the audited financial statements from which it has been derived.

Mitchell Titus, LLP

June 28, 2024

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
 Statements of Financial Position
 As of September 30, 2023 and 2022

	<u>2023</u>	<u>2022</u>
ASSETS		
<i>Current assets</i>		
Cash and cash equivalents	\$ 13,288,090	\$ 18,641,245
Grants and contributions receivables net	82,262,615	73,564,193
Prepaid expenses	51,359	-
Total current assets	<u>95,602,064</u>	<u>92,205,438</u>
<i>Other assets</i>		
Property and equipment net of accumulated depreciation (\$501,625 in 2023 and \$375,601 in 2022)	300,473	5,176
ROU lease asset operating	2,053,791	-
Contributions receivables net	-	228,323
Contract advance	1,915,846	1,151,420
Beneficial interest in assets held by others	960,121	924,575
Other assets	79,274	79,274
Total other assets	<u>5,309,505</u>	<u>2,388,768</u>
Total assets	<u><u>\$ 100,911,569</u></u>	<u><u>\$ 94,594,206</u></u>

The accompanying notes are an integral part of these financial statements.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
 Statements of Financial Position *(continued)*
 As of September 30, 2023 and 2022

	<u>2023</u>	<u>2022</u>
LIABILITIES AND NET ASSETS		
<i>Current liabilities</i>		
Accounts payable and accrued expenses	\$ 36,037,111	\$ 26,798,363
Accrued payroll and benefits	3,244,718	909,873
Other liabilities	14,622,477	22,537,681
Total current liabilities	<u>53,904,306</u>	<u>50,245,917</u>
<i>Other liabilities</i>		
Endowment advance	867,547	867,547
ROU lease liability operating	2,116,945	-
Deferred rent	-	48,177
Total other liabilities	<u>2,984,492</u>	<u>915,724</u>
Total liabilities	<u>56,888,798</u>	<u>51,161,641</u>
<i>Net assets</i>		
Without donor restrictions	13,665,600	8,286,969
With donor restrictions	30,357,171	35,145,596
Total net assets	<u>44,022,771</u>	<u>43,432,565</u>
Total liabilities and net assets	<u>\$ 100,911,569</u>	<u>\$ 94,594,206</u>

The accompanying notes are an integral part of these financial statements.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Statement of Operations and Changes in Net Assets
For the Year Ended September 30, 2023
(With Summarized Financial Information for 2022)

	2023		2022	
	Without Donor Restrictions	With Donor Restrictions	Total	Total
REVENUE AND RECLASSIFICATIONS				
Direct support from federal government	\$ 30,714,070	\$ -	\$ 30,714,070	\$ 20,300,810
Pass-through grants from federal government	67,138,346	-	67,138,346	57,666,822
Contributed nonfinancial assets	4,137,254	-	4,137,254	-
Other grants and contributions	21,497,075	4,081,277	25,578,352	63,405,832
Other	434,952	-	434,952	63,890
Net assets released from restrictions	8,869,702	(8,869,702)	-	-
Total revenue and reclassifications	132,791,399	(4,788,425)	128,002,974	141,437,354
EXPENSES				
Program services	119,082,740	-	119,082,740	132,640,143
Fundraising	181,890	-	181,890	-
Management and general	8,148,138	-	8,148,138	7,207,038
Total expenses	127,412,768	-	127,412,768	139,847,181
Change in net assets	5,378,631	(4,788,425)	590,206	1,590,173
Net assets, at beginning of year	8,286,969	35,145,596	43,432,565	41,842,392
Net assets, at end of year	\$ 13,665,600	\$ 30,357,171	\$ 44,022,771	\$ 43,432,565

The accompanying notes are an integral part of these financial statements.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Statement of Functional Expenses
For the Year Ended September 30, 2023
(With Summarized Financial Information for 2022)

	2023			2022	
	Program Services Expenses	Management and General Expenses	Fundraising	Total Expenses	Total Expenses
Salaries and wages	\$ 27,111,067	\$ 3,901,738	\$ 136,253	\$ 31,149,058	\$ 24,163,552
Fringe benefits	8,133,030	1,169,452	40,874	9,343,356	7,186,385
Subrecipient contract	43,896,085	-	-	43,896,085	40,747,764
Professional fees and other services	376,531	1,134,092	1,500	1,512,122	2,745,049
Contracted direct program expense	38,374,404	783,151	-	39,157,555	63,262,077
Supplies	356,371	35,246	-	391,617	379,421
Occupancy expenses	35,551	722,632	-	758,183	641,370
Equipment	120,947	12,278	-	133,225	382,916
Travel	89,119	203	-	89,322	49,514
Staff development and training expense	539,217	209,695	-	748,912	119,380
Meetings	50,419	19,607	-	70,026	31,365
Printing and materials	-	43,356	3,263	46,619	71,537
Other expenses	-	(4,160)	-	(4,160)	60,198
Depreciation and amortization	-	120,848	-	120,848	6,653
Total expenses	\$ 119,082,740	\$ 8,148,138	\$ 181,890	\$ 127,412,768	\$ 139,847,181

The accompanying notes are an integral part of these financial statements.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
 Statements of Cash Flows
 For the Years Ended September 30, 2023 and 2022

	<u>2023</u>	<u>2022</u>
CASH FLOW FROM OPERATING ACTIVITIES		
Change in net assets	\$ 590,206	\$ 1,590,173
<i>Adjustments to reconcile change in net assets to net cash used in operating activities</i>		
Depreciation and amortization	120,848	6,653
Realized (gain)/loss on sales of investments	-	107
Increase in beneficial interest in assets held by others	(35,546)	(2,371)
<i>Change in operating assets and liabilities</i>		
Change in grants and contributions receivable	(8,470,099)	(37,774,868)
Other receivable		
Change in Contract advances	(764,426)	(1,151,420)
Change in prepaid expense	(51,359)	-
Change in other assets	-	3,981
Change in ROU assets	(2,053,791)	-
Change in accounts payable and accrued expenses	9,238,748	13,455,108
Change in accrued payroll and benefits	2,334,845	166,940
Change in ROU liabilities	2,116,945	-
Change in other liabilities	(7,915,204)	22,537,681
Change in deferred rent	(48,177)	24,670
Net cash used in operating activities	<u>(4,937,010)</u>	<u>(1,143,346)</u>
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of investments	-	-
Sale of investments	-	367,000
Purchase of property and equipment	(416,145)	-
Net cash provided by investing activities	<u>(416,145)</u>	<u>367,000</u>
Net change in cash	(5,353,155)	(776,346)
Cash and cash equivalents, at beginning of year	<u>18,641,245</u>	<u>19,417,591</u>
Cash and cash equivalents, at end of year	<u><u>\$ 13,288,090</u></u>	<u><u>\$ 18,641,245</u></u>

The accompanying notes are an integral part of these financial statements.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 1 ORGANIZATION

Fund for Public Health in New York, Inc. (the Organization) addresses pressing public health needs, fosters private sector support to enhance health and healthcare, and helps to educate the public regarding the protection of individual, family, and community health. The Organization administers programs across the health spectrum, including programs focused on both chronic and communicable diseases. Its programs heighten emergency preparedness, enhance individual and healthcare sector efforts to prevent disease, and support innovation and excellence in public health and healthcare programs.

The Commissioner of the City of New York Department of Health and Mental Hygiene (DOHMH) (Commissioner) recommends 11 members of the Organization's Board of Directors (the Board) following a proposal by the Board's nominating committee and ratification by a majority of the entire Board. In addition, the Commissioner and the Executive Deputy Commissioner of the DOHMH and one member of the City of New York Board of Health, who is selected by the Commissioner, serve ex-officio as members of the Board.

The U.S. Department of Health and Human Services (DHHS) was a significant source of financial support to the Organization during the fiscal year, largely through grants from the Centers for Disease Control and Prevention. The Organization is obligated under the terms of the DHHS's grants to comply with specified conditions and program requirements set forth by the grantor agency.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting and Financial Statement Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) using the accrual basis of accounting.

Net Assets

The Organization's net assets are classified into two categories as follows:

Without Donor Restrictions

Net assets without donor restrictions are expendable for the general operations of the Organization. Such net assets reflect the revenue and expenses associated with the principal operating activities of the Organization and are not subject to donor-imposed stipulations.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Financial Statements
Years Ended September 30, 2023 and 2022

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Net Assets *(continued)*

With Donor Restrictions

Net assets with donor restrictions are limited by donor-imposed stipulations that either expire with the passage of time or can be fulfilled and removed by the actions of the Organization pursuant to those stipulations or include donor-imposed stipulations requiring such resources to be maintained in perpetuity and the income to be utilized for operating or other donor-restricted purposes. When a donor restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of operations and changes in net assets as net assets released from restrictions. At September 30, 2023 and 2022, net assets with donor restrictions only included purpose restrictions.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Summarized Financial Information for Fiscal 2022

The accompanying financial statements include certain prior-year summarized comparative information in total, but not by net asset classification or functional category. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. GAAP. Accordingly, such information should be read in conjunction with the Organization's financial statements for the year ended September 30, 2022 from which the summarized information was derived.

Cash and Cash Equivalents

The Organization maintains its cash in bank deposit accounts that may exceed federally insured limits. The Organization has not experienced any losses in such accounts. All highly liquid investments with maturities of three months or less when purchased are considered to be cash equivalents.

The Organization is required by an anonymous donor to maintain a separate bank account for funds donated for the purpose of establishing an endowment. Conditions made by the donor regarding changes to the status, structure or programmatic nature of the Organization could result in the funds being returned to the donor. Therefore, the Organization has classified the gift as an asset (beneficial interest in assets held by others) and a liability. As of September 30, 2023, and 2022, the Organization held such funds totaling \$960,121 and \$924,575, respectively.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Investments

Investments are certificates of deposit from several banks, which do not exceed federally insured limits. Certificates of deposit are mainly rolled over when due. Maturity dates are 12 months or less. Interest rates range from 0.20% to 4.50% for 2023 and 2022, respectively. The Organization has not experienced any losses in such accounts. Fair value was \$6,644,001 and \$6,448,712 at September 30, 2023 and 2022, respectively.

Beneficial Interest in Assets Held by Others

The Organization has a beneficial interest in assets held by others, which is administered by a third party (see Note 7). The Organization measures its beneficial interest in the trust at fair value of the underlying investments, which are in money market funds (see Note 6 for more information related to the determination of fair value). The amount of the Organization's beneficial interest in assets held by others is offset by a related liability since the agreement from the donor allows for the possibility of the Organization having to return the funds held in beneficial interest. Interest income earned on the beneficial interest in assets held by others is reflected in other income in the accompanying statement of operations and changes in net assets.

Property and Equipment

Property and equipment are recorded at cost or, if donated, at the fair value at the date of donation. Depreciation is recorded on a straight-line basis over the three- to 10-year estimated useful lives of the assets. Leasehold improvements are amortized on a straight-line basis over the estimated useful life of the improvement or the term of the lease, whichever is less. The Organization capitalizes all purchases of property and equipment in excess of \$5,000.

Certain property and equipment are acquired through funds received under Federal grant agreements. According to Federal regulations, any equipment item obtained through Federal funds is subject to a lien by the Federal government. As long as the Organization maintains its tax-exempt status, and so long as the equipment is used for its intended purpose, the Organization is not required to reimburse the Federal funding source. If the stated requirements are not met, the Organization would be obligated to the Federal government in an amount equal to the fair value of the equipment. There were no reimbursements made in 2023 or 2022.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Grants Revenue and Receivable

Grants are recognized as revenue when earned.

Expense-driven grants are recognized as revenue when the qualifying expenses have been incurred and all other grant requirements have been met.

Grants based on meeting performance measures or other deliverables are recorded as revenue as the terms or deliverables are met and accepted by the funder. For such grants, grant funds received prior to the incurrence of the qualifying expenses are recorded as revenue with donor restrictions when milestones are achieved.

At September 30, 2023 and 2022, the Organization had received grants from governmental entities in the aggregate amounts of \$30,714,070 and \$34,180,653, respectively. These grants have not been recorded in the financial statements as they have not been earned.

Contribution Revenue and Receivable

Contributions, including contributed goods and services, are recorded at fair value when received or pledged. Amounts are recorded as revenue with donor restrictions if they have donor stipulations that limit the use of the donated asset. Unconditional contributions that are expected to be collected within one year are recorded at their net realizable value. Unconditional contributions that are expected to be collected beyond one year are recorded at their fair value, using a present value technique, of the estimated future cash flows, discounted at rates adjusted for risk and applicable to the years in which the promises were received. Fair value adjustments of \$0 for both years ended September 30, 2023 and 2022, were recorded to reflect contributions receivable in excess of one year at fair value (see Note 5). Amortization of the discount is credited to contributions revenue. Conditional contributions are recognized as revenue when the conditions on which they depend have been substantially met. There were no conditional contributions received for the years ended September 30, 2023 and 2022.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Financial Statements
Years Ended September 30, 2023 and 2022

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Allowance for Uncollectible Accounts

The carrying value of grants receivable and contributions receivable is reduced by an appropriate allowance for uncollectible accounts, which approximates net realizable value. The Organization determines its allowance by considering several factors, including the length of time receivables are past due, the Organization's previous loss history, the donor's current ability to pay its obligation, and the condition of the general economy and the industry as a whole. Receivables outstanding longer than the payment terms are considered past due. The Organization writes off accounts receivables when they become uncollectible, and payments subsequently received on such receivables are recorded as income in the period received.

It was determined that all grants and contributions receivable as of September 30, 2023 and 2022 will be collected; therefore, no allowance has been established.

Contributed Nonfinancial Assets

As required by accounting standards, the Organization recognizes the fair value of contributed (donated) goods and services when the contributed goods and services: (a) create or enhance nonfinancial assets or (b) require specialized skills, are provided by individuals possessing those skills and would need to be purchased if not provided by donation.

Contributed services totaled \$4,137,254 and \$0 in 2023 and 2022, respectively. In addition, contributed goods totaled \$0 in both 2023 and 2022. Contributed goods and services are reflected as revenue and the corresponding program expense in the accompanying statement of operations and changes in net assets.

Expense Allocations

Expenses that are not specifically attributable to program services or management and general expenses are allocated by management based on variable allocation factors.

Program Management

Salary expenses of \$368,149 and \$345,624 were allocated to programs based on Central Office staff time spent working on the program for the fiscal years ended September 30, 2023 and 2022, respectively.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Tax Status

The Organization was incorporated as a not-for-profit corporation under the laws of the State of New York and is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code. Therefore, there is no provision for income taxes.

Management has analyzed the tax positions taken by the Organization and concluded that as of September 30, 2023 and 2022, there are no uncertain tax positions taken or to be taken. Accordingly, no interest or penalties related to uncertain tax positions have been accrued in the accompanying financial statements.

The Organization is no longer subject to income tax examinations by U.S. Federal, state or local tax authorities for years before 2020, which is the standard statute of limitations look-back period.

Advertising Expenses

As part of its program activity, the Organization incurred advertising expenses of \$143,386 and \$82,169 for the years ended September 30, 2023 and 2022, respectively. Advertising expenses are reflected in the statement of functional expenses under professional fees and other services. Advertising expenses incurred at the time of invoicing are direct expenses to grants and are recorded in accordance with the grant terms and grant period. Advertising expenses are not capitalized.

Reclassification

Certain accounts in the prior-year financial statements have been reclassified for comparative purposes to conform with the presentation of the current-year financial statements.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 3 NEW ACCOUNTING PRONOUNCEMENTS

During 2023, the Organization adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2016-02, *Leases*. ASU 2016-02 changes the accounting for leases, primarily by lessees in operating leases, by requiring: (a) the recognition of (i) a lease asset (right of use) and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position and (ii) a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis, and (b) the classification of all lease payments within the operating activities in the statement of cash flows. Based on the above, the adoption of ASU 2016-02 required the Organization to include on the statements of financial position the value of the right-to-use asset and right-to-use liability and corresponding disclosures. As permitted by the ASU, for leases with a term of 12 months or less as a lessee, the Organization has elected not to recognize lease assets and liabilities and account for the lease similar to existing guidance for operating leases. The guidance did not materially impact the Organization's results of operations.

In addition, during 2023, the Organization also adopted FASB ASU No. 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. The ASU requires nonprofits to change their financial statement presentation and disclosure of contributed nonfinancial assets, or gifts-in-kind. Under the new standard's requirements, gifts-in-kind are to be presented as a separate line item, instead of remaining grouped among contributions of cash or other financial assets, on the statements of activities. The ASU requires the new standard to be applied retrospectively, with amendments taking effect for annual reporting periods beginning after June 15, 2021. Based on the above, contributed nonfinancial assets have been presented separately on the statements of activities for the years ended September 30, 2023 and 2022 and related disclosures updated. The guidance did not materially impact the Organization's results of operations.

NOTE 4 LIQUIDITY AND AVAILABILITY

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, comprise the following:

	September 30, 2023
Cash and cash equivalents	\$ 13,288,090
Grants receivable	81,355,656
Contribution receivable	906,959
Total	\$ 95,550,705

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 4 LIQUIDITY AND AVAILABILITY *(continued)*

As part of its liquidity management, the Organization actively manages operating cash balances to ensure that sufficient cash is available to fund general expenditures as they come due. The Organization is typically able to generate enough operating cash from its ongoing operations to fund general expenditures, but it has procedures in place to utilize other financial assets if necessary. The Organization invests a portion of its cash in excess of daily requirements in certificates of deposit that can be converted to cash in a short period of time in the event of a projected shortfall in operating cash or unanticipated cash need.

NOTE 5 GRANTS AND CONTRIBUTIONS RECEIVABLE

As of September 30, 2023 and 2022, contributions receivable, net, are due as follows:

	<u>2023</u>	<u>2022</u>
Less than one year	\$ 906,959	\$ 2,413,262
One to five years	-	228,323
Total	<u>\$ 906,959</u>	<u>\$ 2,641,585</u>

Management made an assessment of donor risk on contributions receivable outstanding over one year. A risk premium of 0.5% was determined to be appropriate as of September 30, 2023 and 2022, considering the nature and financial integrity of the organizations included in the assessment.

The discount rate applied to contributions receivable in excess of one year consisted of the application of a current two-year Treasury bill rate at that time. Amounts due in more than one year were adjusted to fair value using present value techniques that assumed discount rates of 2.10% for both 2023 and 2022, depending on the length of discount time.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 5 GRANTS AND CONTRIBUTIONS RECEIVABLE (continued)

Grants receivable represented contractual expenses incurred and reimbursable under Federal, state and local grants at September 30, 2023 and 2022 and consisted of the following:

	<u>2023</u>	<u>2022</u>
<i>U.S. Department of Health and Human Services</i>		
Health Resources and Services		
Administration	\$ 877,853	\$ 906,846
Centers for Disease Control	12,112,986	9,183,707
National Institute of Food and Agriculture	780,377	749,572
<i>Agency for Healthcare Research and Quality</i>	570,157	-
State and City of New York Departments of Health	66,395,284	60,297,517
Other	618,998	13,291
Total	<u>\$ 81,355,655</u>	<u>\$ 71,150,933</u>

NOTE 6 FAIR VALUE MEASUREMENTS

The Organization is subject to the provisions of the authoritative guidance issued by the FASB for fair value measurements. The authoritative guidance establishes a framework that provides a fair value hierarchy to prioritize the inputs to valuation techniques used for fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described as:

Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Organization has the ability to access.

Level 2: Inputs to the valuation methodology include: (1) quoted prices for similar assets or liabilities in active markets, (2) quoted prices for identical or similar assets or liabilities in inactive markets, (3) inputs other than quoted prices that are observable for the asset or liability, and (4) inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 6 FAIR VALUE MEASUREMENTS *(continued)*

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Changes in valuation techniques may result in transfers in or out of an assigned level within the hierarchy.

The following describes the valuation methodologies used for assets measured at fair value:

Certificates of deposit and money market accounts (including beneficial interest in assets held by others) – Valuation is derived based on the closing price reported by the investment manager.

The methods used may produce a fair value calculation that may not indicate net realizable value or reflect future fair values. Furthermore, while the Organization believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

There were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2023 and 2022. There were no transfers between levels of the fair value hierarchy.

The following table sets forth by level, within the fair value hierarchy, the Organization's assets at fair value as of September 30, 2023:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Cash and cash equivalents	\$ 821,807	\$ -	\$ -	\$ 821,807
Certificates of deposit	6,644,001	-	-	6,644,001
<i>Beneficial interest in assets held by others</i>				
Money market funds	-	-	960,121	960,121
Total	<u>\$ 7,465,808</u>	<u>\$ -</u>	<u>\$ 960,121</u>	<u>\$ 8,425,929</u>

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Financial Statements
Years Ended September 30, 2023 and 2022

NOTE 6 FAIR VALUE MEASUREMENTS *(continued)*

The following table sets forth by level, within the fair value hierarchy, the Organization's assets at fair value as of September 30, 2022:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Cash and cash equivalents	\$ 821,397	\$ -	\$ -	\$ 821,397
Certificates of deposit	6,488,712	-	-	6,488,712
<i>Beneficial interest in assets held by others</i>				
Money market funds	-	-	924,575	924,575
Total	<u>\$ 7,310,109</u>	<u>\$ -</u>	<u>\$ 924,575</u>	<u>\$ 8,234,684</u>

The beneficial interest in assets held by others contains no liquidity restrictions and is available for withdrawal upon written notice.

The table below sets forth a summary of changes in the fair value of the Organization's Level 3 assets for the years ended September 30, 2023 and 2022:

	<u>2023</u>	<u>2022</u>
Balance, beginning of the year	\$ 924,575	\$ 922,204
Interest income	35,546	2,371
Balance, end of year	<u>\$ 960,121</u>	<u>\$ 924,575</u>

Quantitative Information About Significant Unobservable Inputs Used in Level 3 Fair Value Measurements

The following table represents Level 3 financial instruments, the valuation technique used to measure the fair value of the financial instrument, and the significant unobservable inputs and the ranges of values for those inputs:

<u>Instrument</u>	<u>Fair Value</u>	<u>Principal Valuation Technique</u>	<u>Significant Unobservable Inputs</u>	<u>Ranges of Input Values</u>
Donor-advised fund	\$960,121	Value as reflected in the investment statements from the financial institution holding the beneficial interest instruments	<ul style="list-style-type: none"> ▪ Changes in donor stipulations ▪ Possible withdrawal amount ▪ Possible withdrawal date 	<ul style="list-style-type: none"> ▪ \$0 - \$960,121 ▪ \$0 - \$960,121 ▪ October 1, 2023 and thereafter

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 7 BENEFICIAL INTEREST IN ASSETS HELD BY OTHERS

The Organization received funds from a certain donor to establish an endowment fund. The funds are held and managed by FJC, a foundation of philanthropic funds, as an FJC Earmarked Fund Account, which earns interest quarterly. Under the terms of the agreement, the Organization may spend 5% of the net asset value of the fund annually for general support. The donor reserves the right to designate another Section 501(c)(3) organization to receive this endowment fund if there are changes in the status, structure, or programmatic direction of the Organization that are not satisfactory to the donor. As such, the amount of the beneficial interest is also reported as a liability (endowment advance) in the accompanying statements of financial position. The amount of the endowment advance was \$867,547 at both September 30, 2023 and 2022.

The donor has complete authority and responsibility regarding the investment of the funds. As such, these funds are not subject to any endowment investment policies of the Organization. Furthermore, there is no established fair value regarding the level of the assets to be maintained or stipulations required by the donor concerning the investment.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 8 NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions held by the Organization are summarized below, and are available for the following various program services for the years ended September 30:

Purpose Restrictions

	<u>2023</u>	<u>2022</u>
Administration	\$ 29,250	\$ 29,250
Asthma Care	1,732,112	1,841,311
COVID-19	937,335	357,461
Early Intervention	1,024,399	861,504
Epidemics	12,750	12,750
Healthy Eating	948,062	404,833
Healthy Neighborhoods	425,566	234,675
Honoraria	35,582	49,037
Maternal Health	317,693	312,358
Mental Health	520,281	988,817
Nurse Family Partnership	4,849	4,849
Opioid	16,286	118,452
Other	35,667	42,417
NYC REACH	19,522,227	23,402,626
Quickie Lab	465,389	718,581
Racial Justice and Health Equity	914,134	370,494
School Based Health	3,406,681	5,387,274
ThriveNYC	8,907	8,907
Total	<u><u>\$ 30,357,171</u></u>	<u><u>\$ 35,145,596</u></u>

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 8 NET ASSETS WITH DONOR RESTRICTIONS *(continued)*

Net assets released from donor restrictions because of expenses incurred satisfying the restricted purposes during the years ended September 30 were as follows:

Released from Restrictions

	<u>2023</u>	<u>2022</u>
Asthma Care	\$ -	\$ 41,210
COVID-19	109,199	2,124,748
Early Intervention	144,060	817,466
Foodborne Disease	737,105	-
Healthy Eating	-	35,083
Healthy Neighborhoods	450,608	51,258
Hepatitis C	9,090	-
Opioid	13,954	31,548
Other	1,514	-
HIV Testing	468,536	-
Honoraria	-	1,678
Maternal Health	102,166	731
Mental Health	6,725	223,934
NYC REACH	4,035,988	734,919
Quickie Lab	261,529	-
Racial Justice and Health Equity	528,500	287,133
School Based Health	2,000,729	2,689,530
STI Testing	-	2
ThriveNYC	-	25,004
Tuberculosis	-	-
Total	<u>\$ 8,869,702</u>	<u>\$ 7,064,245</u>

NOTE 9 PENSION PLAN

The Organization has a defined contribution pension plan covering substantially all full-time employees who meet certain eligibility requirements. The amount contributed to the plan is a fixed percentage of participants' compensation. Net pension expense amounted to \$974,053 and \$840,499 for the years ended September 30, 2023 and 2022, respectively.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 10 CONTINGENCIES

Certain grants and contracts may be subject to audit by the funding sources. Such audits might result in adjustments to reimbursements claimed by the Organization for the various programs conducted for or on behalf of the funding sources. In management's opinion, any potential adjustments resulting from such audits would not have a material effect on the accompanying financial statements.

NOTE 11 LEASE COMMITMENT

In May 2011, the Organization leased new office space in New York City. In May 2015, the Organization extended the term of the lease from July 31, 2016 to February 2024. Rent through July 2016 was charged in accordance with the original agreement and after July 2016 rent is in accordance with the extended agreement. On November 16, 2021, the lease was extended to June 30, 2027, and for a larger space.

The Organization recognizes lease liabilities and their corresponding right-of-use assets at the lease commencement date, and initially measures the lease liabilities and right-of-use assets using the present value of lease payments over the defined lease term discounted using the incremental borrowing rate or risk-free rate.

The Organization's lease has fixed rental payments that have annual rent increases as stipulated in the lease agreement. The Organization also makes separate payments to the lessor based on the lessor's real estate taxes assessed on the property, utilities as well as a portion of the common area maintenance and operations associated with the property. The Organization has elected the practical expedient not to separate lease and non-lease components for the building lease.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Financial Statements
Years Ended September 30, 2023 and 2022

NOTE 11 LEASE COMMITMENT *(continued)*

During 2023 and 2022, the Organization recognized rent expenses associate with the lease as follows:

	<u>2023</u>	<u>2022</u>
<i>Operating lease cost</i>		
Fixed rent expense	\$ 591,653	\$ -
Variable rent expense (reduction)	73,325	-
Short-term lease cost	-	-
Net lease cost	<u>\$ 664,978</u>	<u>\$ -</u>
Lease cost - operating expenses	\$ 39,930	\$ -
Lease cost - depreciation	547,678	-
Lease cost - interest	77,370	-
Net lease cost	<u>\$ 664,978</u>	<u>\$ -</u>

During the year ended September 30, 2023, cash and non-cash activities associated with the Organization's lease is as follows:

<i>Cash paid for amounts in the measurement of lease liabilities</i>	
Operating cash flows from operating leases	<u>\$ 649,402</u>
<i>Non-cash investing and financing activities</i>	
New operating lease liabilities	<u>\$ -</u>

Other Information

Remaining lease term – operating leases	3 years 9 months
Discount rate – operating leases	2.92%

Future minimum annual payments as follows:

<u>Year Ending September 30,</u>	<u>Amount</u>
2024	\$ 568,486
2025	615,556
2026	627,867
2027	477,928
Total	2,289,837
Less: Effects of discounting	(172,892)
Lease liabilities recognized	<u>\$ 2,116,945</u>

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Notes to Financial Statements

Years Ended September 30, 2023 and 2022

NOTE 12 CONCENTRATION OF CREDIT/REVENUE RISKS

Cash is exposed to various risks, such as interest rate, market and credit risks. To minimize such risks, the Organization maintains its cash in various bank deposit accounts that may exceed federally insured limits. At September 30, 2023 and 2022, the Organization's cash was placed into high credit quality financial institutions and, accordingly, the Organization does not anticipate any losses with respect to these depository accounts. The Organization's mission is to provide fiscal management and support for public health programs in New York City through its partnership with the DOHMH. Therefore, all program activity is concentrated within the New York City geographic region. During the fiscal years ended 2023 and 2022, the Organization received 86%, of its Federal funding from the CDC. Such funding accounted for 20% of the Organization's total revenue. The Organization also received a significant portion of its funding from the city accounted for 69% and 38% of the Organization's total revenue for fiscal years ended 2023 and 2022, respectively.

Due to the concentration of funds from Federal, New York State and New York City sources, there is a risk that the Organization would not be able to continue in its current capacity or support certain programs if this source of funding was to be lost. Management is confident that the Organization would continue to be able to perform its functions through reductions and cost-cutting measures as a result of the unique nature of its partnership with the DOHMH.

NOTE 13 PROPERTY AND EQUIPMENT

Property and equipment, net, at September 30, 2023 and 2022 consisted of the following:

	<u>2023</u>	<u>2022</u>
Leasehold improvements	\$ 194,094	\$ 48,429
Furniture and fixtures	472,998	216,440
Computer software and hardware	129,830	115,908
Total cost	796,922	380,777
Less: Accumulated depreciation	496,449	375,601
Property and equipment, net	<u>\$ 300,473</u>	<u>\$ 5,176</u>

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Financial Statements
Years Ended September 30, 2023 and 2022

NOTE 14 SUBSEQUENT EVENTS

The Organization evaluates events occurring after the date of the financial statements to consider whether the impact of such events needs to be reflected or disclosed in the financial statements. Such evaluation was performed through June 28, 2024, the date these financial statements were available for issuance.

**SUPPLEMENTARY INFORMATION AND
INDEPENDENT AUDITOR'S REPORTS**

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.

Schedule of Expenditures of Federal Awards

For the Year Ended September 30, 2023

<u>Federal Grantor/Pass Through Grantor/Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Pass-Through Entity Identifying Number</u>	<u>Passed Through to Subrecipients</u>	<u>Total Federal Expenditures</u>
United States Department of Homeland Security				
<i>Federal Emergency Management Agency</i>				
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
COVID-19 - Disaster Grants - Public Assistance (Presidentially Declared Disasters) (2/12/2021-6/30/2022)	97.036	21FB054601R0X00	\$ -	\$ 404,305
Total Disaster Grants - Public Assistance (Presidentially Declared Disasters)			-	404,305
Total United States Department of Homeland Security			-	404,305
United States Department of Health and Human Services				
<i>Centers for Disease Control and Prevention</i>				
Cooperative Agreements for Diabetes Control Programs (6/30/2023-06/29/2028)	93.988	N/A	-	30,487
Total Cooperative Agreements for Diabetes Control Programs			-	30,487
Injury Prevention and Control Research and State and Community Based Programs (9/1/2019-08/31/2023)	93.136	N/A	-	3,090,014
Injury Prevention and Control Research and State and Community Based Programs (9/1/2023-08/31/2024)	93.136	N/A	-	40,239
Total Injury Prevention and Control Research and State and Community Based Programs			-	3,130,253
The Innovative Cardiovascular Health Program (9/30/2022-9/29/2023)	93.435	N/A	156,483	2,296,989
Total Innovative Cardiovascular Health Program			156,483	2,296,989
COVID-19 - Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises (6/1/2021-8/31/2024)	93.391	N/A	19,205,265	21,037,514
Total COVID-19 - Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises			19,205,265	21,037,514
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/30/2024)	93.268	22FB001501R0X00	7,926,962	8,442,369
COVID-19 - Immunization Cooperative Agreements (7/1/2022-6/30/2023)	93.268	22FB001501R0X00	11,171,807	12,691,394
COVID-19 - Immunization Cooperative Agreements (9/1/2023-12/31/2024)	93.268	22FB012601R0X00	-	42,212
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/30/2024)	93.268	22FB001501R0X00	-	205,629
COVID-19 - Immunization Cooperative Agreements (7/1/2022-6/30/2023)	93.268	22FB001501R0X00	-	1,921,298

See accompanying notes.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Schedule of Expenditures of Federal Awards (*continued*)
For the Year Ended September 30, 2023

<u>Federal Grantor/Pass Through Grantor/Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Pass-Through Entity Identifying Number</u>	<u>Passed Through to Subrecipients</u>	<u>Total Federal Expenditures</u>
United States Department of Health and Human Services (<i>continued</i>)				
<i>Passed through New York City Department of Health and Mental Hygiene</i> (<i>continued</i>)				
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/20/2024)	93.268	22FB001501R0X00	\$ -	\$ 463,962
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/30/2024)	93.268	22FB012501R0X00	-	125,697
COVID-19 - Immunization Cooperative Agreements (7/1/2022-6/20/2023)	93.268	22FB001501R0X00	-	1,866,665
COVID-19 - Immunization Cooperative Agreements (10/1/2022-9/30/2023)	93.268	22FB001501R0X00	-	2,357,768
Total COVID-19 - Immunization Cooperative Agreements			19,098,769	28,116,994
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	-	162,113
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	-	31,146
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	-	156,384
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	-	1,273,242
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-7/31/2023)	93.323	22FB001501R0X00	-	143,355
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB001501R0X00	-	135,439
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	-	520,533
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB001501R0X00	-	1,715,865
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB001501R0X00	-	504,827
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	-	3,143,194
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB001501R0X00	-	561,763
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	-	838,749
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	-	2,089,723
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	-	115,767
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB001501R0X00	-	88,302
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	-	66,547
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	-	2,589,329
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	-	2,952,556
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-7/31/2024)	93.323	22FB012501R0X00	-	4,300,706
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012601R0X00	-	204,289
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-7/31/2023)	93.323	22FB012601R0X00	-	274,308
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-7/31/2023)	93.323	22FB012601R0X00	-	63,082
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2023)	93.323	22FB012601R0X00	-	127,693
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2023)	93.323	22FB012601R0X00	-	1,751,113
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2023)	93.323	22FB012601R0X00	-	1,152,517
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2024)	93.323	22FB012601R0X00	-	490,247
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-7/31/2023)	93.323	22FB012601R0X00	-	247,701

See accompanying notes.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Schedule of Expenditures of Federal Awards *(continued)*
For the Year Ended September 30, 2023

<u>Federal Grantor/Pass Through Grantor/Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Pass-Through Entity Identifying Number</u>	<u>Passed Through to Subrecipients</u>	<u>Total Federal Expenditures</u>
United States Department of Health and Human Services <i>(continued)</i>				
<i>Passed through New York City Department of Health and Mental Hygiene (continued)</i>				
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2024)	93.323	22FB012601R0X00	\$ -	\$ 118,169
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2024)	93.323	22FB012601R0X00	-	67,788
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2024)	93.323	22FB012601R0X00	-	2,939,083
Total Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)			-	28,825,530
Project Grants and Cooperative Agreements for Tuberculosis Control Programs (7/1/2022-6/30/2023)	93.116	22FB001501R0X00	-	471,659
Project Grants and Cooperative Agreements for Tuberculosis Control Programs (7/1/2022-6/30/2023)	93.116	22FB001501R0X00	-	42,199
Total Project Grants and Cooperative Agreements for Tuberculosis Control Programs			-	513,858
Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees (7/1/2022-6/30/2023)	93.478	22FB012601R0X00	-	286,712
Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees (7/1/2022-6/30/2023)	93.478	22FB012601R0X00	-	16,196
Total Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees			-	302,908
Capacity Building Assistance (CBA) for High-Impact HIV Prevention (7/1/2023-6/30/2024)	93.834	22FB012601R0X00	-	100,000
Capacity Building Assistance (CBA) for High-Impact HIV Prevention (7/1/2023-6/30/2024)	93.834	22FB012601R0X00	-	17,870
Total Capacity Building Assistance for High -Impact HIV Prevention			-	117,870
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (9/1/2021-6/30/2023)	93.944	22FB012601R0X00	-	164,171
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (8/1/2022-6/30/2023)	93.944	22FB012601R0X00	-	30,814
Total Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance			-	194,985
HIV Prevention Activities Health Department Based (7/1/2022-6/30/2023)	93.940	22FB012601R0X00	-	86,000
HIV Prevention Activities Health Department Based (7/1/2022-6/30/2023)	93.940	22FB012601R0X00	-	195,215
Total HIV Prevention Activities Department of Health			-	281,215
Sexually Transmitted Diseases (STD) Prevention and Control Grants (7/1/2022-6/30/2023)	93.977	22FB012601R0X00	-	35,483
Sexually Transmitted Diseases (STD) Prevention and Control Grants (7/1/2022-6/30/2023)	93.977	N/A	-	5,075
Total Sexually Transmitted Diseases (STD) Prevention and Control Grants			-	40,558

See accompanying notes.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Schedule of Expenditures of Federal Awards (*continued*)
For the Year Ended September 30, 2023

<u>Federal Grantor/Pass Through Grantor/Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Pass-Through Entity Identifying Number</u>	<u>Passed Through to Subrecipients</u>	<u>Total Federal Expenditures</u>
Substance Abuse and Mental Health Services Administration				
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED) (7/1/2022-6/30/2024)	93.104	22FB012601R0X00	\$ -	\$ 94,355
Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED) (7/1/2022-6/30/2024)	93.104	22FB012601R0X00	-	<u>7,285</u>
Total Comprehensive Community Mental Health Service for Children with serious Emotional Disturbances (SED)			<u>-</u>	<u>101,640</u>
Administration for Children and Families				
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
<i>477 Cluster</i>				
Child Care and Development Block Grant (7/1/2022-6/30/2023)	93.575	22FB001501R0X00	-	24,215
Child Care and Development Block Grant (7/1/2022-6/30/2023)	93.575	22FB001501R0X00	-	190,061
Child Care and Development Block Grant (7/1/2022-6/30/2023)	93.575	22FB001501R0X00	-	<u>26,759</u>
Total Child Care and Development Block Grant			<u>-</u>	<u>241,035</u>
Total 477 Cluster			<u>-</u>	<u>241,035</u>
Office of Assistant Secretary for Health				
Teenage Pregnancy Prevention Program (7/1/2022-6/30/2023)	93.297	N/A	-	1,034,395
Teenage Pregnancy Prevention Program (7/1/2023-6/30/2024)	93.297	N/A	-	<u>150,615</u>
Total Teenage Pregnancy Prevention Program			<u>-</u>	<u>1,185,010</u>
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
COVID-19 - Community Programs to Improve Minority Health Grant Program (7/1/2022-6/30/2023)	93.137	22FB012601R0X00	633,717	848,251
Community Programs to Improve Minority Health Grant Program (7/1/2022-6/30/2023)	93.137	22FB012601R0X00	-	<u>138,951</u>
Total Community Programs to Improve Minority Health Grant Program			<u>633,717</u>	<u>987,202</u>
Health Resources and Services Administration				
Healthy Start Initiative (4/1/2022-3/31/2023)	93.926	N/A	253,226	494,013
Healthy Start Initiative (4/1/2019-4/30/2024)	93.926	N/A	<u>314,977</u>	<u>474,861</u>
Total Healthy Start Initiative			<u>568,203</u>	<u>968,874</u>

See accompanying notes.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Schedule of Expenditures of Federal Awards (*continued*)
For the Year Ended September 30, 2023

<u>Federal Grantor/Pass Through Grantor/Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Pass-Through Entity Identifying Number</u>	<u>Passed Through to Subrecipients</u>	<u>Total Federal Expenditures</u>
Health Resources and Services Administration (<i>continued</i>)				
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
HIV Emergency Relief Project Grants (7/1/2022-6/30/2023)	93.914	22FB012601R0X00	\$ -	\$ 2,614,692
Total HIV Emergency Relief Project Grants			-	2,614,692
Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Program Parts A and B	93.686	N/A	-	87,588
Total Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Program Parts A and B			-	87,588
Administration for Community Living (HHS-ACL)				
<i>Passed through National Council on Aging</i>				
COVID-19 - Special Programs for the Aging, Title IV, and Title II, Discretionary Projects (5/17/2023-4/30/2024)	93.048	N/A	-	1,110
Total COVID-19 - Special Programs for the Aging, Title IV, and Title II, Discretionary Projects			-	1,110
Research and Development Cluster				
<i>Agency for Healthcare Research and Quality</i>				
Research on Healthcare Costs, Quality and Outcomes (9/30/2020-09/29/2023)	93.226	N/A	110,269	431,050
Total Research on Healthcare Costs, Quality and Outcomes			110,269	431,050
Centers for Disease Control and Prevention				
Environmental Public Health and Emergency Response (09/30/20-09/29/25)	93.070	N/A	-	188,489
Total Environmental Public Health and Emergency Response			-	188,489
National Institutes of Health				
<i>Passed through New York University</i>				
COVID-19 - Nursing Research (07/01/2020-06/30/2024)	93.361	21-A0-00-1007163	28,499	65,670
Total COVID-19 - Nursing Research			28,499	65,670
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
Diabetes, Digestive, and Kidney Diseases Extramural Research (7/1/2021-6/30/2023)	93.847	22FB012601R0X00	-	130,142
Diabetes, Digestive, and Kidney Diseases Extramural Research (7/1/2021-6/30/2023)	93.847	22FB012601R0X00	-	2,301
Total Diabetes, Digestive, and Kidney Diseases Extramural Research			-	132,443

See accompanying notes.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Schedule of Expenditures of Federal Awards (*continued*)
For the Year Ended September 30, 2023

<u>Federal Grantor/Pass Through Grantor/Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Pass-Through Entity Identifying Number</u>	<u>Passed Through to Subrecipients</u>	<u>Total Federal Expenditures</u>
National Institutes of Health (<i>continued</i>)				
<i>Passed through New York City Department of Health and Mental Hygiene</i> (<i>continued</i>)				
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (7/1/2022-6/30/2023)	93.840	22FB012601R0X00	\$ -	\$ 439,981
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (7/1/2022-6/30/2023)	93.840	22FB012601R0X00	-	<u>28,956</u>
Total Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders			<u>-</u>	<u>468,937</u>
Total Research and Development Cluster			<u>138,768</u>	<u>1,286,589</u>
Total United States Department of Health and Human Services			<u>39,801,205</u>	<u>92,362,901</u>
United States Department of Housing and Urban Development				
Assistant Secretary for Community Planning and Development				
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
Housing Opportunities for Persons with AIDS (7/1/2022-8/31/2023)	14.241	22FB012601R0X00	-	376,000
Housing Opportunities for Persons with AIDS (7/1/2022-8/31/2023)	14.241	22FB012601R0X00	-	<u>32,954</u>
Total Housing Opportunities for Persons with AIDS			<u>-</u>	<u>408,954</u>
Total United States Department of Housing and Urban Development			<u>-</u>	<u>408,954</u>
United States Department of Agriculture				
National Institute of Food and Agriculture				
COVID-19 - Gus Schumacher Nutrition Incentive Program (8/1/2021-7/31/2025)	10.331	N/A	-	189,695
Gus Schumacher Nutrition Incentive Program (9/1/2020-8/31/2024)	10.331	N/A	-	<u>1,255,584</u>
Total Gus Schumacher Nutrition Incentive Program			<u>-</u>	<u>1,445,279</u>

See accompanying notes.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
 Schedule of Expenditures of Federal Awards (*continued*)
 For the Year Ended September 30, 2023

<u>Federal Grantor/Pass Through Grantor/Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Pass-Through Entity Identifying Number</u>	<u>Passed Through to Subrecipients</u>	<u>Total Federal Expenditures</u>
Food and Nutrition Service				
<i>Passed through New York City Department of Health and Mental Hygiene</i>				
<i>Supplemental Nutrition Assistance Program Cluster</i>				
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (7/1/2022-6/30/2023)	10.561	22FB012601R0X00	\$ -	\$ 346,757
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (7/1/2021-6/30/2024)	10.561	22FB012601R0X00	-	689,266
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (7/1/2021-6/30/2024)	10.561	22FB012601R0X00	-	13,985
Total State Administrative Matching Grants for the Supplemental Nutrition Assistance Program			-	1,050,008
Total Supplemental Nutrition Assistance Program Cluster			-	1,050,008
Natural Resources Conservation Service				
Soil and Water Conservation (6/1/2023 - 3/31/2024)	10.902	N/A	-	127
Total Soil and Water Conservation			-	127
Total United States Department of Agriculture			-	2,495,414
Total Federal Awards Passed Through to Subrecipients			<u>\$ 39,801,205</u>	
Total Federal Awards				<u>\$ 95,671,574</u>

See accompanying notes.

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Schedule of Expenditures of Federal Awards
For the Year Ended September 30, 2023

NOTE 1 BASIS OF PRESENTATION

The accompanying schedule of expenditures of federal awards (the Schedule) includes the Federal grant and contract activity of the Organization under the programs of the federal government for the year ended September 30, 2023. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* (CFR) Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the Organization, it is not intended to, and it does not, present the financial position, changes in net assets, or cash flows of the Organization.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

Expenditures reported on the Schedule are on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The Organization has elected not to use the 10% de minimis indirect cost rate allowed under the Uniform Guidance.

NOTE 3 SUBRECIPIENTS

The Organization provided Federal awards to subrecipients, as follows:

Program Title	Federal Assistance Listing Number	Subrecipient	Amount Provided to Subrecipient
The Innovative Cardiovascular Health Program (9/30/2022-9/29/2023)	93.435	New York City Department of Health and Mental Hygiene (NYC DOHMH), 85079	\$ 156,483
		Subtotal	<u>156,483</u>
COVID-19 - Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises (6/1/2021-8/31/2024)	93.391	84484, Jewish Community Council of Greater Cone	978,559
		84502, Fund for the City of New York	911,952
		84503, Boro Park Jewish Community Council	1,147,835
		84504, ReServe Elder Services	179,833
		84505, Destination Tomorrow	1,117,953
		84506, Haitian Americans United for Progress	900,857
		84688, Mexican Coalition for the Empowerment of Brooklyn Bureau Of Community Service Db	975,184
		Community Services, 84297	1,005,038
		Hebrew Educational Society of Brooklyn, 84292	1,058,463
		India Home, 84406	1,090,290
		Jewish Community Council of Greater Coney Island, 84362	606,566
		Latino Commission on AIDS, 84301	1,261,452
		Little Sisters of the Assumption Family Health Services Inc, 84296	944,707
		National Black Leadership Commission on AIDS, 84293	915,517
		Not Applicable	1,416,376
		Phipps Neighborhoods, Inc., 84294	644,870
		Project Hospitality, 84416	1,084,067
		Public Health Solutions, 84414	1,002,272
		ReServe Elder Services, Inc., 84298	1,036,832
		The Central Family Life Center, Inc., 84336	<u>926,642</u>
		Subtotal	<u>19,205,265</u>

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Schedule of Expenditures of Federal Awards *(continued)*
For the Year Ended September 30, 2023

NOTE 3 SUBRECIPIENTS *(continued)*

Program Title	Federal Assistance Listing Number	Subrecipient	Amount Provided to Subrecipient		
COVID-19 - Immunization Cooperative Agreements(7/1/2021-6/30/2024)	93.268	84698, ACT Care Foundation, Inc.	\$ 99,388		
		84699, AD-Deen, Inc.	97,834		
		84700, African International Collaborative Cent	89,848		
		84702, Arab-American Family Support Center, Inc.	53,896		
		84703, Bangladeshi American Community Development	133,732		
		84704, Bronx Christian Fellowship Baptist Church	125,382		
		84705, BronxWorks, Inc.	55,936		
		84706, CAMBA, Inc.	97,540		
		84707, Caribbean Women's Health Association, Inc.	219,298		
		84708, Cypress Hills Local Development Corporation	70,151		
		84709, Diaspora Community Services	2,304		
		84710, Every Day Is A Miracle	268,389		
		84711, Fund for the City of New York	57,856		
		84712, Grand Concourse Seventh-day Adventist Church	61,684		
		84713, Holy Tabernacle #1 Church of God in Christ	82,352		
		84715, Life Church	82,098		
		84716, Morris Heights Health Center	381,766		
		84717, Neighborhood Housing Services of Brooklyn	49,984		
		84718, Neighborhood Initiatives Development Corp.	115,939		
		84719, Relume Foundation Inc.	249,144		
		84720, Rockaway Waterfront Alliance, Inc.	72,940		
		84721, Sauti Yetu Center for African Women & Fa	118,696		
		84722, Transnational Villages Network/ Red de P	108,460		
		84723, Under 21 d/b/a Covenant House New York	24,984		
		84724, United Sikhs	103,760		
		84725, Vocational Instruction Project Community	104,464		
		84726, Word of Life International, Inc.	110,846		
		84761, Jewish Orthodox Women's Medical Associates	331,306		
		84762, ODA Primary Healthcare Network	54,553		
		84763, Staten Island Not for Profit Association	181,566		
		84764, Negotiated Acquisition â€” Federal	224,327		
		84952, Brooklyn Bureau of Community Service	731,719		
		84953, CABS Home Attendants Service, Inc.	1,155,185		
		84954, Community Health Action of Staten Island	1,231,089		
		84955, Harlem Congregations for Community Improvement	532,578		
		85133, Phoenix Houses of Long Island Inc.	248,323		
		84956, Phoenix Houses of Long Island Inc.	197,645		
			Subtotal		<u>7,926,962</u>
		COVID-19 - Immunization Cooperative Agreements (7/1/2022-6/30/2023)	93.268	84727, Beacon Christian Community Health Center	370,156
				84728, Brownsville Community Development Corpor	1,431,219
				84729, Charles B. Wang Community Health Center	821,721
				84730, Damian Family Care Centers	100,214
				84731, East Harlem Council for Human Services,	607,674
				84732, Essen Medical Urgicare, PLLC	1,292,897
				84733, L'Refuah Medical & Rehabilitation Center	592,471
				84734, First MedCare	320,404
				84735, Jamaica Hospital Medical Center	592,195
				84736, LaSante Health Center, Inc.	631,976
				84737, Morris Heights Health Center	559,418
				84738, Premium Health, Inc.	1,345,043
				84739, HASC DIAGNOSTIC AND TREATMENT CENTER, IN	645,192
				84740, The William F. Ryan Community Health Cen	1,355,129
				84741, Episcopal Health Services Inc dba St. John	724,213
				84742, Sun River Health Inc DBA Hudson River He	1,025,484
				84743, Union Community Health Center	1,402,466
84744, Urban Health Plan	556,196				
	Test Contact				<u>(3,202,261)</u>
	Subtotal				<u>11,171,807</u>
COVID-19 - Community Programs to Improve Minority Health Grant Program (7/1/2022-6/30/2023)	93.137	84982, RiseBoro Community Partnership, Inc.	241,290		
		84983, Rebecca Scott dba Sustainable Snacks	100,849		
		84997, Endangered Language Alliance	108,746		
		85145, Rebecca Scott dba Sustainable Snacks	71,739		
		85146, Endangered Language Alliance	60,356		
		85185, Samuel Field YM & YWHA, Inc.	50,737		
	Subtotal		<u>633,717</u>		

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Schedule of Expenditures of Federal Awards *(continued)*
For the Year Ended September 30, 2023

NOTE 3 SUBRECIPIENTS *(continued)*

<u>Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Subrecipient</u>	<u>Amount Provided to Subrecipient</u>
Healthy Start Initiative (4/1/2022-3/31/2023)	93.926	84560, Brooklyn Perinatal Network	\$ 10,835
		84597, Caribbean Women's Health Association, In	22,007
		84623, New York City Department of Health and M	218,280
		84752, The Brookdale Hospital Medical Center	2,104
		Subtotal	<u>253,226</u>
Healthy Start Initiative (4/1/2019-4/30/2024)	93.926	85075, Caribbean Women's Health Association, In	16,987
		85087, Brooklyn Perinatal Network	10,350
		85178, NYC Dept. of Health and Mental Hygiene	246,685
		85186, The Brookdale Hospital Medical Center	40,955
		Subtotal	<u>314,977</u>
Research on Healthcare Costs, Quality and Outcomes (9/30/2020-09/29/2023)	93.226	85078, NYC Dept. of Health and Mental Hygiene	27,719
		84995, NYU Medical Center dba NYU School of Medicine	82,550
		Subtotal	<u>110,269</u>
COVID-19 - Nursing Research (07/01/2020-06/30/2024)	93.361	85081, NYC Dept. of Health and Mental Hygiene	28,499
		Subtotal	<u>28,499</u>
		Grand total	\$ 39,801,205

NOTE 4 RECONCILIATION OF SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS TO AUDITED FINANCIAL STATEMENTS

The total expenditures, as reflected in the Schedule, vary from the amount reported in the statement of operations and changes in net assets as Federal revenue due to the inclusion of several pass-through contracts as well as Federal expenditures that were paid for via program revenue or other matching funds. The revenue related to these reconciling items is reflected in other grants and contributions revenue in the accompanying statement of operations and changes in net assets. The reconciling items are listed below:

Total expenses per SEFA schedule		\$ 95,671,574	
<i>Less: Pass throughs</i>			
<u>Federal Grantor/Pass-Through Grantor/Program Title</u>	<u>Federal Assistance Listing Number</u>	<u>Pass-Through Grant #</u>	<u>Amount</u>
<i>Passed-through New York City Department of Health and Mental Hygiene</i>			
COVID-19 - Disaster Grants - Public Assistance (Presidentially Declared Disasters) (2/12/2021-6/30/2022)	97.036	N/A	\$ 404,305
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/30/2024)	93.268	22FB001501R0X00	8,442,369
COVID-19 - Immunization Cooperative Agreements (7/1/2022-6/30/2023)	93.268	22FB001501R0X00	12,691,394
COVID-19 - Immunization Cooperative Agreements (9/1/2023-12/31/2024)	93.268	22FB012601R0X00	42,212
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/30/2024)	93.268	22FB001501R0X00	205,629
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/30/2023)	93.268	22FB001501R0X00	1,921,298
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/20/2024)	93.268	22FB001501R0X00	463,962
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/30/2024)	93.268	22FB012501R0X00	125,697
COVID-19 - Immunization Cooperative Agreements (7/1/2022-6/20/2023)	93.268	22FB001501R0X00	1,866,666
COVID-19 - Immunization Cooperative Agreements (10/1/2022-9/30/2023)	93.268	22FB001501R0X00	2,357,768
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	162,113
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	31,146
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	156,384
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	1,273,242
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-7/31/2023)	93.323	22FB001501R0X00	143,355
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB001501R0X00	135,439
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	520,533
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB001501R0X00	1,715,865
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB001501R0X00	504,827
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	3,143,194
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB001501R0X00	561,763
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	838,749
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	2,089,723
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	115,767
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB001501R0X00	88,302
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012501R0X00	66,547
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	2,589,329

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Notes to Schedule of Expenditures of Federal Awards *(continued)*
For the Year Ended September 30, 2023

NOTE 4 RECONCILIATION OF SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS TO AUDITED FINANCIAL STATEMENTS *(continued)*

Federal Grantor/Pass-Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Grant #	Amount
Passed through New York City Department of Health and Mental Hygiene <i>(continued)</i>			
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	\$ 2,952,556
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-7/31/2024)	93.323	22FB012501R0X00	4,300,706
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2023)	93.323	22FB012601R0X00	204,289
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-7/31/2023)	93.323	22FB012601R0X00	274,308
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-7/31/2023)	93.323	22FB012601R0X00	63,082
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2023)	93.323	22FB012601R0X00	127,693
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2023)	93.323	22FB012601R0X00	1,751,113
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2023)	93.323	22FB012601R0X00	1,152,517
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2024)	93.323	22FB012601R0X00	490,247
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-7/31/2023)	93.323	22FB012601R0X00	247,701
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2024)	93.323	22FB012601R0X00	118,169
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2024)	93.323	22FB012601R0X00	67,788
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2024)	93.323	22FB012601R0X00	2,939,083
Project Grants and Cooperative Agreements for Tuberculosis Control Programs (7/1/2022-6/30/2023)	93.116	22FB001501R0X00	471,659
Project Grants and Cooperative Agreements for Tuberculosis Control Programs (7/1/2022-6/30/2023)	93.116	22FB001501R0X00	42,199
Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees (7/1/2022-6/30/2023)	93.478	22FB012601R0X00	286,712
Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees (7/1/2022-6/30/2023)	93.478	22FB012601R0X00	16,196
Capacity Building Assistance (CBA) for High-Impact HIV Prevention (7/1/2023-6/30/2024)	93.834	22FB012601R0X00	100,000
Capacity Building Assistance (CBA) for High-Impact HIV Prevention (7/1/2023-6/30/2024)	93.834	22FB012601R0X00	17,870
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (9/1)	93.944	22FB012601R0X00	164,171
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (8/1)	93.944	22FB012601R0X00	30,814
HIV Prevention Activities Health Department Based (7/1/2022-6/30/2023)	93.940	22FB012601R0X00	86,000
HIV Prevention Activities Health Department Based (7/1/2022-6/30/2023)	93.940	22FB012601R0X00	195,215
Sexually Transmitted Diseases (STD) Prevention and Control Grants (7/1/2022-6/30/2023)	93.977	22FB012601R0X00	35,483
Sexually Transmitted Diseases (STD) Prevention and Control Grants (7/1/2022-6/30/2023)	93.977	N/A	5,075
Comprehensive Community Mental Health Service for Children with serious Emotional Disturbances (SED) (93.104	22FB012601R0X00	94,355
Comprehensive Community Mental Health Service for Children with serious Emotional Disturbances (SED) (93.104	22FB012601R0X00	7,285
Child Care and Development Block Grant (7/1/2022-6/30/2023)	93.575	22FB001501R0X00	24,215
Child Care and Development Block Grant (7/1/2022-6/30/2023)	93.575	22FB001501R0X00	190,060
Child Care and Development Block Grant (7/1/2022-6/30/2023)	93.575	22FB001501R0X00	26,759
COVID-19 - Community Programs to Improve Minority Health Grant Program (7/1/2022-6/30/2023)	93.137	22FB012601R0X00	848,251
Community Programs to Improve Minority Health Grant Program (7/1/2022-6/30/2023)	93.137	22FB012601R0X00	138,951
HIV Emergency Relief Project Grants (7/1/2022-6/30/2023)	93.914	22FB012601R0X00	2,614,692
Ending the HIV Epidemic: A Plan for America-Ryan White HIV/AIDS Program Parts A and B	93.686	N/A	87,588
Passed through National Council on Aging			
COVID-19 - Special Programs for the Aging, Title IV, and Title II, Discretionary Projects (5/17/2023-4/30/202	93.048	N/A	1,110
Passed through New York University			
COVID-19 - Nursing Research (07/01/2020-06/30/2024)	93.361	21-A0-00-1007163	65,670
Passed through New York City Department of Health and Mental Hygiene			
Diabetes, Digestive, and Kidney Diseases Extramural Research (7/1/2021-6/30/2023)	93.847	22FB012601R0X00	130,142
Diabetes, Digestive, and Kidney Diseases Extramural Research (7/1/2021-6/30/2023)	93.847	22FB012601R0X00	2,301
Translation and implementation Science Research for Heart, Lung, Blood, Diseases and Sleep Disorders (7	93.840	22FB012601R0X00	439,981
Translation and implementation Science Research for Heart, Lung, Blood, Diseases and Sleep Disorders (7	93.840	22FB012601R0X00	28,956
Passed through New York City Department of Health and Mental Hygiene <i>(continued)</i>			
Housing Opportunities for Persons with AIDS (7/1/2022-8/31/2023)	14.241	22FB012601R0X00	\$ 376,000
Housing Opportunities for Persons with AIDS (7/1/2022-8/31/2023)	14.241	22FB012601R0X00	32,954
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (7/1/2022-6/30/202	10.561	22FB012601R0X00	346,757
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (7/1/2021-6/30/202	10.561	22FB012601R0X00	689,266
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (7/1/2021-6/30/202	10.561	22FB012601R0X00	13,985
Subtotal passthrough adjustments			64,957,502
Add: Other adjustments			
Rounding adjustment			(2)
Subtotal other adjustments			(2)
SEFA federal revenue adjusted			30,714,070
Federal revenue per financial statement			\$ 30,714,070



**INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER
FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED
ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE
WITH GOVERNMENT AUDITING STANDARDS**

To Management and the Board of Directors
Fund for Public Health in New York, Inc.

We have audited in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Fund for Public Health in New York, Inc. (the Organization), which comprise the statement of financial position as of September 30, 2023, the related statements of operations and changes in net assets, functional expenses and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated June 28, 2024.

Report on Internal Control over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Organization's internal control over financial reporting (internal control) as a basis for designing procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, we do not express an opinion on the effectiveness of the Organization's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

80 Pine Street
New York, NY 10005
T +1 212 709 4500
F +1 212 709 4680
mitchelltitus.com



MITCHELL TITUS

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Organization’s financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity’s internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Mitchell Titus, LLP

June 28, 2024



**INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH
MAJOR FEDERAL PROGRAM AND REPORT ON INTERNAL CONTROL
OVER COMPLIANCE IN ACCORDANCE WITH THE UNIFORM GUIDANCE**

To Management and the Board of Directors
Fund for Public Health in New York, Inc.

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Fund for Public Health in New York, Inc.'s (the Organization) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Organization's major federal programs for the year ended September 30, 2023. The Organization's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Organization complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Organization's compliance with the compliance requirements referred to above.

80 Pine Street
New York, NY 10005
T +1 212 709 4500
F +1 212 709 4680
mitchelltitus.com



Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Organization's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Organization's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Organization's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Organization's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Organization's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.



Report on Internal Control over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit, we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Mitchell Titus, LLP

June 28, 2024

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
 Schedule of Findings and Questioned Costs
 For the Year Ended September 30, 2023

SECTION I—SUMMARY OF AUDITOR’S RESULTS

Financial Statements

Type of auditor’s report issued (unmodified, qualified, adverse, or disclaimer):

Unmodified

Internal control over financial reporting:

- Material weakness(es) identified? Yes X No
- Significant deficiency(ies) identified? Yes X None Reported
- Noncompliance material to financial statements noted? Yes X No

Federal Awards

Internal control over major federal programs:

- Material weakness(es) identified? Yes X No
- Significant deficiency(ies) identified? Yes X None Reported

Type of auditor's report issued on compliance for major federal programs (unmodified, qualified, adverse, or disclaimer):

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 Yes X No

Identification of major federal programs:

<u>Federal Assistance Listing Number(s)</u>	<u>Name of Federal Program or Cluster</u>
93.136	Injury Prevention and Control Research and State and Community Based Programs
93.268	COVID-19 – Immunization Cooperative Agreements

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.
Schedule of Findings and Questioned Costs *(continued)*
For the Year Ended September 30, 2023

SECTION I—SUMMARY OF AUDITOR’S RESULTS *(continued)*

Dollar threshold used to distinguish
between type A and type B programs: \$2,870,147

Auditee qualified as low-risk auditee? X Yes No

SECTION II—FINANCIAL STATEMENT FINDINGS

No matters were reported.

SECTION III—FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

No matters were reported.

SECTION IV—PRIOR-YEAR AUDIT FINDINGS

See page 46.

FPHNY FY23 Audit Responses

SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS For the Year Ended September 30, 2023

Audit Finding Reference: 2022-001

Inadequate Controls over Financial Reporting

Status of Prior Finding: This finding was corrected during fiscal year ended September 30, 2023. The corrective action plan was fully implemented by September 30, 2023, as the Fund improved the account reconciliation process and related controls, including:

- Developed and notified employees of new standard operating procedures (SOP) for the finance and accounting departments on how to prepare and document reconciliation templates to ensure consistency. This includes assigning each account to a preparer and a reviewer. The reconciliations are done on a monthly basis, completed after the standard closing entries have been entered but before the analytical review.
- Engaged JMT Consulting, expert implementation partners for nonprofit organizations using Sage Intacct accounting software, to rectify the historical account balance transfer related issues and provide additional training to the employees on the new software operations.

The Fund believes our corrective actions accomplished the objective to strengthen internal controls over financial reporting.

Audit Finding Reference: 2022-002

Federal Funding Accountability and Transparency Act (FFATA) Reporting

Status of Prior Finding: This finding was corrected during fiscal year ended September 30, 2023. The corrective action plan was fully implemented by November 1, 2023, as the Fund updated its internal procedures to enhance tracking and monitoring, including requiring that the FFATA reports are prepared and then reviewed by the preparer's supervisor prior to submission. The Fund also now ensures that appropriate staff are notified and trained on the requirements and updated process. Management now monitors this issue regularly during the year to ensure compliance. The Fund believes our corrective actions accomplished the objective to strengthen internal controls over and ensure compliance with FFATA reporting requirements.

